S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Our #1 Laser Stock for May (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Tragedy that left 5 dead or missing puts spotlight on safety in Alaska charter fishing industry
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Forecast, Price & News

$0.79
+0.04 (+5.33%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.73
$0.79
50-Day Range
$0.64
$0.87
52-Week Range
$0.61
$5.09
Volume
283,913 shs
Average Volume
255,682 shs
Market Capitalization
$50.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.46

Taysha Gene Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
941.9% Upside
$8.23 Price Target
Short Interest
Healthy
3.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$3,400 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.87) to ($0.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

121st out of 983 stocks

Biological Products, Except Diagnostic Industry

15th out of 164 stocks


TSHA stock logo

About Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

TSHA Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Q1 2023 Taysha Gene Therapies Inc Earnings Call
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
See More Headlines

TSHA Price History

TSHA Company Calendar

Last Earnings
3/28/2023
Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TSHA
Fax
N/A
Employees
38
Year Founded
2020

Price Target and Rating

Average Stock Price Forecast
$8.23
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+971.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$-166,010,000.00
Pretax Margin
-1,849.60%

Debt

Sales & Book Value

Annual Sales
$2.50 million
Book Value
($0.23) per share

Miscellaneous

Free Float
55,707,000
Market Cap
$50.70 million
Optionable
Not Optionable
Beta
1.17

Social Links


Key Executives

  • Mr. R. A. Session IIMr. R. A. Session II (Age 43)
    Founder, Pres, CEO & Director
    Comp: $542.95k
  • Mr. Kamran Alam CPAMr. Kamran Alam CPA (Age 44)
    M.B.A., Chief Financial Officer
    Comp: $395.51k
  • Dr. Suyash Prasad FFPM (Age 52)
    M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M, Chief Medical Officer and Head of R&D
    Comp: $617.34k
  • Mr. Frederick Porter Ph.D.
    Chief Technical Officer
  • Mr. Jim Rouse
    Chief Information Officer
  • Ms. Tracy M. Porter
    Chief People Officer
  • Ms. Emily McGinnis M.P.H.
    Chief Patient Officer & Head of Gov. Affairs
  • Ms. Mishima Gerhart
    Chief Regulatory Officer & Head of Quality
  • Mr. Sean McAuliffe
    Chief Commercial Officer
  • Mr. Greg Gara
    Sr. VP of Manufacturing













TSHA Stock - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 4 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares.
View TSHA analyst ratings
or view top-rated stocks.

What is Taysha Gene Therapies' stock price forecast for 2023?

14 brokerages have issued 12-month price targets for Taysha Gene Therapies' shares. Their TSHA share price forecasts range from $2.00 to $19.00. On average, they expect the company's share price to reach $8.23 in the next year. This suggests a possible upside of 941.9% from the stock's current price.
View analysts price targets for TSHA
or view top-rated stocks among Wall Street analysts.

How have TSHA shares performed in 2023?

Taysha Gene Therapies' stock was trading at $2.26 at the start of the year. Since then, TSHA shares have decreased by 65.0% and is now trading at $0.79.
View the best growth stocks for 2023 here
.

Are investors shorting Taysha Gene Therapies?

Taysha Gene Therapies saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 1,190,000 shares, a drop of 31.2% from the April 30th total of 1,730,000 shares. Based on an average trading volume of 401,900 shares, the short-interest ratio is currently 3.0 days. Currently, 3.2% of the company's stock are short sold.
View Taysha Gene Therapies' Short Interest
.

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our TSHA earnings forecast
.

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.58. The company had revenue of $2.50 million for the quarter.

When did Taysha Gene Therapies IPO?

(TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies served as the underwriters for the IPO and Chardan was co-manager.

What is Taysha Gene Therapies' stock symbol?

Taysha Gene Therapies trades on the NASDAQ under the ticker symbol "TSHA."

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (4.81%), Acadian Asset Management LLC (0.63%), BlackRock Inc. (0.62%), Geode Capital Management LLC (0.59%), Quantum Private Wealth LLC (0.56%) and Renaissance Technologies LLC (0.39%). Insiders that own company stock include Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends
.

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taysha Gene Therapies' stock price today?

One share of TSHA stock can currently be purchased for approximately $0.79.

How much money does Taysha Gene Therapies make?

Taysha Gene Therapies (NASDAQ:TSHA) has a market capitalization of $50.70 million and generates $2.50 million in revenue each year. The company earns $-166,010,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis.

How can I contact Taysha Gene Therapies?

Taysha Gene Therapies' mailing address is 2280 Inwood Road, DALLAS TX, 75235. The official website for the company is www.tayshagtx.com. The company can be reached via phone at 214-612-0000 or via email at investors@tayshagtx.com.

This page (NASDAQ:TSHA) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -